Overview
This is a non-interventional multi-database post-authorisation study to assess pregnancy-related safety data from women with SLE exposed to Anifrolumab.
Description
The aim of this study is to describe congenital malformations, adverse pregnancy and birth outcomes in pregnancies/offspring from women with moderate/severe SLE exposed to anifrolumab during pregnancy and to compare with outcomes in women with moderate/severe SLE who are exposed to other standard of care but not anifrolumab. Adverse outcomes related to infant growth up to one year of age will also be investigated.
Eligibility
Inclusion criteria for EXPOSED SOURCE POPULATION:
- Women with a continuous enrolment in the database for ≥ 12 months prior to LMP2
- Women diagnosed with SLE before pregnancy
- Women exposed to anifrolumab (polytherapy, added to SLE SOC) during pregnancy and/or 16-week period prior to LMP2
Exclusion criteria for EXPOSED SOURCE POPULATION:
\- Pregnancies whose date of conception cannot be established
Inclusion criteria for UNEXPOSED SOURCE POPULATION:
- Women with a continuous enrolment in the database for ≥ 12 months prior to LMP2
- Women diagnosed with SLE before pregnancy
- Women treated with SLE SOC during pregnancy
Exclusion criteria for UNEXPOSED SOURCE POPULATION:
- Women treated with anifrolumab during pregnancy and/or 16-week period prior to LMP2
- Pregnancies whose date of conception cannot be established
Inclusion criteria for EXPOSED and UNEXPOSED STUDY POPULATION:
\- Women with moderate/severe SLE
Exclusion criteria for EXPOSED and UNEXPOSED STUDY POPULATION:
- Women with a history of CM or chromosomal abnormalities (according to available records), before delivery
- Women prescribed a confirmed teratogenic drug prior to LMP2 with a time period of 5-half-lives of relevant drug or during pregnancy
